What are the most common mistakes with PEG-MGF?
The most common PEG-MGF mistakes are treating it as MGF-equivalent (different kinetics); daily dosing (the long half-life means weekly is sufficient); long cycles without safety data. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for PEG-MGF is limited.
Common PEG-MGF mistakes
- Treating it as MGF-equivalent (different kinetics)
- Daily dosing (the long half-life means weekly is sufficient)
- Long cycles without safety data
Bloodwork worth tracking
- IGF-1 baseline + at week 4
- Fasting glucose every 2 weeks
References
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation — Yang SY & Goldspink G, FEBS Letters, 2002
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? — Zabłocka B, Goldspink PH, Goldspink G, Górecki DC, Frontiers in Endocrinology, 2012
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PEG-MGF
Last updated 2026-06-15.